Anastrobull 1 - Bull Pharma

Launched in 1995 by Zeneca Pharmaceuticals, anastrozole entered the medical field as a refined solution to hormone-dependent breast cancer. Unlike earlier drugs such as tamoxifen, it did not block estrogen receptors but instead inhibited aromatase, the enzyme responsible for converting androgens into estrogens. Its impact was validated through the ATAC study, which compared its effectiveness to tamoxifen in over 9,000 women. The study’s results in 2002 confirmed its role as a new clinical standard for postmenopausal patients.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anastrobull 1 by Bull Pharma, consult with your doctor or healthcare professional.